ClinicalTrials.gg
TerminatedNCT03081390Updated Oct 6, 2026

Migraine and CVD Risk in Women

An interventional study of Mixed meal tolerance testing and Skin conductance & cold pressor test in Migraine, sponsored by University of Pennsylvania. Terminated at 2 sites in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Other

How we know

Why this study was terminated
Investigator transition
Updated Oct 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
513th of 610
23 · median 78
Started
2017
with 45 others
No phase
204 of 697
31 open now
Registered
334th of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 513th largest by enrollment of the 610 interventional ones that give a count, is one of 46 that started in 2017, is one of 204 with no phase, and was the 334th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The primary goal of this study is to test the effects of a high-fat, high-carbohydrate mixed meal on candidate modulators of cardiovascular disease risk (inflammation, vascular reactivity, sympathetic nervous system tone, and response to pain) in young adult women with migraine compared with healthy young women. This is study enrolling both cases (women with migraine) and controls (women without migraine), with equal numbers of normal weight and obese women in each group. Participants will undergo a telephone screening and a single day in-person study visit.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (all):

  • Female 18-35 years of age, inclusive
  • 18.5-24.9 kg/m2, inclusive
  • BMI ≥30 kg/m2

Inclusion Criteria (cases only):

  • Diagnosis of migraine per ICHD-3-beta (1-10 migraine days per month)

Exclusion Criteria (all):

  • Smoking (current or former)
  • Chronic use of medications, including oral
  • Major medical or psychiatry illness (e.g. diabetes, fibromyalgia, major depression/anxiety)
  • Pregnant or nursing
  • Allergies or sensitivity to any of the ingredients of the meal
  • Inability to fast for 10 hours and/or abstain from caffeine intake for 24 hours
  • Treatment with antibiotics or within the previous 3 months
  • Treatment with NSAIDs within the previous 1 week

Exclusion Criteria (controls only):

  • Migraine headaches, or headaches other than tension-type headaches with a frequency of 1 or fewer days per month
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    No migraine, normal weight

    * Mixed meal tolerance testing * Skin conductance \& cold pressor test * Flow-mediated dilation testing

    Other: Mixed meal tolerance testing · Other: Skin conductance & cold pressor test · Other: Flow-mediated dilation testing

  • Experimental
    No migraine, obese

    * Mixed meal tolerance testing * Skin conductance \& cold pressor test * Flow-mediated dilation testing

    Other: Mixed meal tolerance testing · Other: Skin conductance & cold pressor test · Other: Flow-mediated dilation testing

  • Experimental
    Migraine, normal weight

    * Mixed meal tolerance testing * Skin conductance \& cold pressor test * Flow-mediated dilation testing

    Other: Mixed meal tolerance testing · Other: Skin conductance & cold pressor test · Other: Flow-mediated dilation testing

  • Experimental
    Migraine, obese

    * Mixed meal tolerance testing * Skin conductance \& cold pressor test * Flow-mediated dilation testing

    Other: Mixed meal tolerance testing · Other: Skin conductance & cold pressor test · Other: Flow-mediated dilation testing

Interventions

  • OtherMixed meal tolerance testing

    An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.

  • OtherSkin conductance & cold pressor test

    Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.

  • OtherFlow-mediated dilation testing

    At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.

06

What researchers measure

Primary outcomes

  1. LPS area under the curve (AUC)

    The primary study endpoint is lipopolysaccharide (LPS) area under the curve (AUC) during MMTT.

    Time frame: LPS is measured at baseline every 30 minutes for 4 hours.

Secondary outcomes

  1. Flow-mediated dilation (FMD)

    Vascular reactivity via brachial artery ultrasound, expressed as flow-mediated dilation (% of baseline diameter, normalized).

    Time frame: FMD is measured at baseline and 2.5 hours after MMTT.

  2. Sympathetic tone at rest and with painful stimulus

    Sympathetic tone via skin conductance is expressed as mean skin conductance level (SCL) in microsiemens, and assessed at rest and following a pain stimulus (cold pressor test).

    Time frame: Sympathetic tone at rest and with painful stimulus are measured at baseline and 3 hours after MMTT.

07

Study locations

2 sites
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19004, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: Yes — After the primary publication is complete, interested investigators can request these data without identifiers. The study team will evaluate the request for scientific rigor and ensure consistency with our protocol, and then provide data without identifiers via secure file-share. This will include the subset of participants who indicated their data could be used for ancillary and/or future studies.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2017 to primary completion in Sep 2026, 113 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Jun 2020 → Sep 2026 and completion Jun 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2017
First posted
Mar 16, 2017
StartActual
Apr 1, 2017
Primary completionActual
Sep 28, 2026was Jun 2020
CompletionActual
Sep 28, 2026was Jun 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Investigator transition
changed Oct 6, 2026
Primary completion
Jun 30, 2020→Sep 28, 2026
Oct 6, 2026
Study completion
Jun 30, 2026→Sep 28, 2026 (actual)
Oct 6, 2026
Enrollment
30 (estimated)→23 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Terminated
    Why stopped Investigator transition
    Primary completion Jun 30, 2020→Sep 28, 2026
    Study completion Jun 30, 2026→Sep 28, 2026 (now actual)
    Enrollment 30 (estimated)→23 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03081390
Responsible party
Sponsor
First posted
Mar 16, 2017
Start date
Apr 1, 2017
Primary completion
Sep 28, 2026
Completion
Sep 28, 2026
Last update
Oct 6, 2026

Study contacts

Shana E McCormack, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion